SEC Form 4 filed by Myers Jason W.

$ISO
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Get the next $ISO alert in real time by email
SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
X
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Myers Jason W.

(Last) (First) (Middle)
C/O ISOPLEXIS CORPORATION
35 NE INDUSTRIAL ROAD

(Street)
BRANFORD CT 06405

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
IsoPlexis Corp [ ISO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
03/21/2023
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Rule 10b5-1(c) Transaction Indication

  
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option $10.7163 03/21/2023 D 40,000 (2) 07/21/2031 Common Stock 40,000 (1) 0 D
Stock Option $2.1 03/21/2023 D 89,047 (3) 06/16/2032 Common Stock 89,047 (1) 0 D
Explanation of Responses:
1. On March 21, 2023, pursuant to the Agreement and Plan of Merger, dated as of December 21, 2022 (the Merger Agreement), by and among IsoPlexis Corporation, a Delaware corporation (IsoPlexis), Berkeley Lights, Inc., a Delaware corporation (Berkeley Lights), and Iceland Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of Berkeley Lights, each IsoPlexis stock option reported in this Form 4 that was (a) vested and unexercised or (b) vested solely as a result of the consummation of the merger pursuant to the Merger Agreement was, in each case, exercisable prior to the effective time of such merger and, to the extent unexercised at such effective time, canceled for no consideration.
2. Vested 25% on July 19, 2022 and thereafter in 36 equal monthly installments.
3. Vests in full on the earlier of June 16, 2023 or the day prior to the next annual stockholders meeting.
/s/ Jason W. Myers 03/21/2023
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $ISO alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ISO

DatePrice TargetRatingAnalyst
2/15/2022$17.00 → $12.00Overweight
Morgan Stanley
1/27/2022$20.00 → $15.00Outperform
SVB Leerink
11/19/2021$24.00Outperform
Evercore ISI Group
11/11/2021$17.00 → $20.00Outperform
SVB Leerink
11/2/2021$17.00Outperform
SVB Leerink
11/2/2021Outperform
Cowen & Co.
11/2/2021$16.00Overweight
Morgan Stanley
More analyst ratings

$ISO
Press Releases

Fastest customizable press release news feed in the world

See more
  • Berkeley Lights Completes Acquisition of IsoPlexis Forming PhenomeX, the Functional Cell Biology Company

    PhenomeX to begin trading under symbol (NASDAQ:CELL) EMERYVILLE, Calif., March 21, 2023 /PRNewswire/ -- Berkeley Lights, Inc. (NASDAQ:BLI), a life sciences tools company, today announced that it has completed its previously announced acquisition of IsoPlexis Corporation (NASDAQ:ISO), a company empowering labs to leverage the cells and proteome changing the course of human health. The newly combined company has been renamed PhenomeX and its common stock will begin trading on Nasdaq under the ticker symbol "CELL" at market open tomorrow. PhenomeX is positioned to be the leading

    $BLI
    $ISO
    Medicinal Chemicals and Botanical Products
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • IsoPlexis Reports Preliminary Full Year 2022 Revenue

    BRANFORD, Conn., Jan. 12, 2023 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (NASDAQ: ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced its preliminary unaudited revenue for the full year ended December 31, 2022. Total revenue for the full year ended December 31, 2022 is expected to be in the range of $16.6 to $16.8 million, representing a decrease of approximately 3% to 4% compared to $17.3 million for the full year ended December 31, 2021. Fourth quarter results were lower than expected primarily due to the timing of customer orders for instruments and lower consumable sales, as the previously described macroeconomic head

    $ISO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
  • Berkeley Lights to Acquire IsoPlexis, Creating a Premier Functional Cell Biology Company

    Complementary Technologies, Customer Bases, and Commercial Channels to Strengthen Leadership in High-Growth, Single-Cell Biology Significant Cost Synergies to Increase Profitability and Accelerate Breakeven Horizon in 2024, Earlier Than Berkeley Lights Expected as a Standalone Entity Companies to Host Joint Conference Call and Webcast Today at 5:00 p.m. ET EMERYVILLE, CA and BRANFORD, Conn., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Berkeley Lights (NASDAQ:BLI), a life sciences tools company, and IsoPlexis (NASDAQ:ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced a definitive agreement under which Berkeley Lights will acquire

    $BLI
    $ISO
    Medicinal Chemicals and Botanical Products
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus

$ISO
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$ISO
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$ISO
Leadership Updates

Live Leadership Updates

See more
  • IsoPlexis Appoints Key Financial and Legal Hires from Leading Tools and Omics Companies

    BRANFORD, Conn., Nov. 30, 2021 /PRNewswire/ -- IsoPlexis (NASDAQ: ISO), the leader in functional single-cell proteomics, today announced the appointment of Richard Rew as Senior VP, General Counsel and Secretary; Raj Khakhar as VP of Finance; and Manny Resendes as Global Controller. These three new appointments further strengthen Isoplexis' financial and legal teams. "We are excited to have Mr. Rew, Mr. Khakhar, and Mr. Resendes join our team at IsoPlexis," said Sean Mackay, CEO of IsoPlexis. "These recent hires will strengthen our ability to accelerate our growth trajectory a

    $ISO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
  • IsoPlexis Bolsters Its Global Operational and Product Support Leadership

    BRANFORD, Conn., Nov. 12, 2021 /PRNewswire/ -- IsoPlexis (NASDAQ:ISO), the leader in functional single-cell proteomics, today announced the appointment of two new leadership positions at the company. Michelle Reid, Ph.D. joins IsoPlexis as VP of Service and Support, and Anthony Catalano joins as the Senior VP of Operations. With these appointments, IsoPlexis continues to strengthen its operations and product support teams, providing high need proteomic products with highly customer centric support. Ms. Reid comes to IsoPlexis with over 20 years of experience leading and devel

    $ISO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
  • IsoPlexis Bolsters Its Global Operational and Product Support Leadership

    BRANFORD, Conn., Nov. 12, 2021 /PRNewswire/ -- IsoPlexis (NASDAQ:ISO), the leader in functional single-cell proteomics, today announced the appointment of two new leadership positions at the company. Michelle Reid, Ph.D. joins IsoPlexis as VP of Service and Support, and Anthony Catalano joins as the Senior VP of Operations. With these appointments, IsoPlexis continues to strengthen its operations and product support teams, providing high need proteomic products with highly customer centric support. Ms. Reid comes to IsoPlexis with over 20 years of experience leading and devel

    $ISO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

$ISO
Financials

Live finance-specific insights

See more
  • Berkeley Lights to Acquire IsoPlexis, Creating a Premier Functional Cell Biology Company

    Complementary Technologies, Customer Bases, and Commercial Channels to Strengthen Leadership in High-Growth, Single-Cell Biology Significant Cost Synergies to Increase Profitability and Accelerate Breakeven Horizon in 2024, Earlier Than Berkeley Lights Expected as a Standalone Entity Companies to Host Joint Conference Call and Webcast Today at 5:00 p.m. ET EMERYVILLE, CA and BRANFORD, Conn., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Berkeley Lights (NASDAQ:BLI), a life sciences tools company, and IsoPlexis (NASDAQ:ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced a definitive agreement under which Berkeley Lights will acquire

    $BLI
    $ISO
    Medicinal Chemicals and Botanical Products
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • Berkeley Lights to Acquire IsoPlexis, Creating a Premier Functional Cell Biology Company

    Complementary Technologies, Customer Bases, and Commercial Channels to Strengthen Leadership in High-Growth, Single-Cell Biology Significant Cost Synergies to Increase Profitability and Accelerate Breakeven Horizon in 2024, Earlier Than Berkeley Lights Expected as a Standalone Entity Companies to Host Joint Conference Call and Webcast Today at 5:00 p.m. ET EMERYVILLE, Calif. and BRANFORD, Conn., Dec. 21, 2022 /PRNewswire/ -- Berkeley Lights (NASDAQ:BLI), a life sciences tools company, and IsoPlexis (NASDAQ:ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced a definitive agreement under which Berkeley Lights will acquire IsoP

    $BLI
    $ISO
    Medicinal Chemicals and Botanical Products
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • IsoPlexis to Report Third Quarter 2022 Financial Results on November 10, 2022

    BRANFORD, Conn., Oct. 19, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (NASDAQ:ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced it will report financial results for the third quarter 2022 before market open on Thursday, November 10, 2022. Company management will be webcasting a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.isoplexis.com. The webcast will be archived and available for replay after the event. About IsoPlexis IsoPlexis is empowering labs to leverage the ce

    $ISO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

$ISO
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more